Devonian Health Group Inc. reports developments as a clinical-stage biopharmaceutical company focused on therapies for fibro-inflammatory diseases. Company news centers on Thykamine™, including preclinical data in MASH and pulmonary fibrosis models, anti-inflammatory and anti-fibrotic research, intellectual-property filings, manufacturing controls and its radiodermatitis prevention program.
Recurring updates also cover Devonian's cosmeceutical activities, its Quebec extraction facility and Altius Healthcare Group LP, a commercialization subsidiary that sells licensed prescription pharmaceutical products in Canada. Corporate news includes financial results, board and management changes, shareholder meeting outcomes, stock-option grants and capital-structure actions such as its common-share consolidation.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Devonian Health Group has announced that during its annual shareholder meeting on March 17, 2023, shareholders approved the renewal of its stock option plan and restricted share unit plan. Both plans are designed as '10% rolling' plans, allowing the issuance of shares equal to 10% of the outstanding shares. Amendments to comply with TSX Venture Exchange policies were also made, including new rules for the vesting and expiry of options and share units, and provisions for insiders. The plans remain subject to final approval from the Exchange.